^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    alextatug (ATRC-101)

    i
    Other names: ATRC-101, ATRC 101, mATRC-101
    Associations

    News

    Trials
    Company:
    Atreca
    Drug class:
    RNP inhibitor
    Associations

    News

    Trials
    2years
    A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies (clinicaltrials.gov)
    P1, N=87, Terminated, Atreca, Inc. | Phase classification: P1b --> P1 | N=240 --> 87 | Trial completion date: Mar 2025 --> Nov 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Nov 2023; Sponsor Decision
    Phase classification • Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
    |
    TMB-H • MSI-H/dMMR • BRAF mutation
    |
    Keytruda (pembrolizumab) • pegylated liposomal doxorubicin • alextatug (ATRC-101)
    over2years
    A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies (clinicaltrials.gov)
    P1b, N=240, Active, not recruiting, Atreca, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
    |
    TMB-H • MSI-H/dMMR • BRAF mutation
    |
    Keytruda (pembrolizumab) • pegylated liposomal doxorubicin • alextatug (ATRC-101)
    over4years
    A Dose Escalation Trial of ATRC-101 in Adults With Advanced Solid Malignancies (clinicaltrials.gov)
    P1b, N=160, Recruiting, Atreca, Inc. | N=65 --> 160
    Clinical • Enrollment change • Combination therapy
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR • BRAF mutation
    |
    Keytruda (pembrolizumab) • alextatug (ATRC-101)
    almost6years
    [VIRTUAL] First-in-human phase Ib study of ATRC-101, an engineered version of a patient-derived antibody targeting a tumor-restricted ribonucleoprotein complex. (ASCO 2020)
    Secondary objectives are to characterize the pharmacokinetic profiles of ATRC-101 and to assess antitumor activity as determined by RECIST 1.1 and lymphocytic infiltration in the tumor microenvironment. Research Funding: Atreca, Inc.
    Clinical • P1 data
    |
    CD8 (cluster of differentiation 8)
    |
    alextatug (ATRC-101)